David Fournier

Practice Areas

David Fournier is an experienced intellectual property attorney who focuses his practice on developing and implementing complex IP and market exclusivity strategies for emerging and mature life sciences companies as well as advising on regulatory matters related to their most successful products.

With academic training in biology and biotechnology and over 25 years of professional experience, Dave advises clients on global product exclusivity planning and patent portfolio development. Dave has guided patent portfolio development and lifecycle management strategies for dozens of marketed innovator pharmaceutical and medical device products with billions of dollars in global revenue. He has also developed global patent portfolios for several developmental stage biologics, including peptides, stem cell therapies, antibody-drug conjugates and cell therapeutics.

In addition to participating in abbreviated new drug application (ANDA) district court litigations and appeals, Dave has counseled clients on Orange and Purple Book listing and Use Code strategy, patent term extensions and adjustments, FDA exclusivity and pre-ANDA litigation strategy. He also has experience with a variety of post-grant proceedings, including reissues, reexaminations, European oppositions, inter partes reviews and post-grant review. 

In addition to his patent procurement, regulatory and post-grant practice, Dave leads intellectual property due diligence assessments related to venture capital and private equity financings, public offerings, asset acquisitions, technology spin-outs and royalty monetization deals. He conducts patent landscape analyses; renders opinions on freedom-to-operate, inventorship, validity, and patentability issues; drafts and negotiates patent license agreements; and mines mature patent portfolios for opportunities to maximize value.

Prior to becoming a lawyer, Dave worked in clinical research and as a patent agent with Pfizer and its legacy companies. His graduate research focused on the characterization of protein kinase C isozyme expression in human endometrial carcinomas and its correlation with various clinicopathic disease features.